PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.78%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.51%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
49.59%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.87%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
190.40%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.03%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
190.40%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.95%. Joel Greenblatt would see if unique processes drive exceptional profitability.
171.27%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.45%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
162.90%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.12%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
162.90%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 14.47%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
2.26%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.43%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-28.58%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-32.85%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
1211.10%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.85%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
736.04%
3Y CAGR of 736.04% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-600.11%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3629.51%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-19942.46%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
175.53%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.37% over a decade. Joel Greenblatt might see a standout compounder of earnings.
37300.27%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 3.44%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-73.74%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is -11.99%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4319.20%
Equity/share CAGR of 4319.20% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
1522.06%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 14.35%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
48.90%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.15%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Receivables shrinking more than Drug Manufacturers - Specialty & Generic median. Joel Greenblatt might see strong working capital management or a shift to cash sales.
47.19%
Inventory growth of 47.19% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
3.70%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.03%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
3.02%
BV/share growth of 3.02% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-4.80%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
4.80%
R&D growth of 4.80% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
0.20%
SG&A dropping significantly vs. Drug Manufacturers - Specialty & Generic median. Joel Greenblatt sees near-term margin upside but checks for underinvestment risk.